Next Article in Journal
Molecular Docking, Computational, and Antithrombotic Studies of Novel 1,3,4-Oxadiazole Derivatives
Previous Article in Journal
A Graded Multifunctional Hybrid Scaffold with Superparamagnetic Ability for Periodontal Regeneration
Previous Article in Special Issue
Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of F9 into rDNA Locus of Mouse ESCs

DNA Vaccines—How Far From Clinical Use?

Department of Dermatology, University Medical Center, 55131 Mainz, Germany
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(11), 3605;
Received: 15 October 2018 / Revised: 7 November 2018 / Accepted: 9 November 2018 / Published: 15 November 2018
(This article belongs to the Special Issue Gene Therapy)
Two decades ago successful transfection of antigen presenting cells (APC) in vivo was demonstrated which resulted in the induction of primary adaptive immune responses. Due to the good biocompatibility of plasmid DNA, their cost-efficient production and long shelf life, many researchers aimed to develop DNA vaccine-based immunotherapeutic strategies for treatment of infections and cancer, but also autoimmune diseases and allergies. This review aims to summarize our current knowledge on the course of action of DNA vaccines, and which factors are responsible for the poor immunogenicity in human so far. Important optimization steps that improve DNA transfection efficiency comprise the introduction of DNA-complexing nano-carriers aimed to prevent extracellular DNA degradation, enabling APC targeting, and enhanced endo/lysosomal escape of DNA. Attachment of virus-derived nuclear localization sequences facilitates nuclear entry of DNA. Improvements in DNA vaccine design include the use of APC-specific promotors for transcriptional targeting, the arrangement of multiple antigen sequences, the co-delivery of molecular adjuvants to prevent tolerance induction, and strategies to circumvent potential inhibitory effects of the vector backbone. Successful clinical use of DNA vaccines may require combined employment of all of these parameters, and combination treatment with additional drugs. View Full-Text
Keywords: DNA vaccine; nano carrier; promotor; transgene; adjuvant; antigen presenting cells; dendritic cell; macrophage DNA vaccine; nano carrier; promotor; transgene; adjuvant; antigen presenting cells; dendritic cell; macrophage
Show Figures

Figure 1

MDPI and ACS Style

Hobernik, D.; Bros, M. DNA Vaccines—How Far From Clinical Use? Int. J. Mol. Sci. 2018, 19, 3605.

AMA Style

Hobernik D, Bros M. DNA Vaccines—How Far From Clinical Use? International Journal of Molecular Sciences. 2018; 19(11):3605.

Chicago/Turabian Style

Hobernik, Dominika, and Matthias Bros. 2018. "DNA Vaccines—How Far From Clinical Use?" International Journal of Molecular Sciences 19, no. 11: 3605.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop